OBJECTIVE: This study aimed to evaluate the impact of pregnancy-related immune events on the HIV-1 replication and to analyze their relationship with the risk of vertical transmission. METHODS: The peripheral blood from HIV-1-infected pregnant women who controlled (G1) or not controlled (G2) their plasma viral load was drawn, and the plasma and the T cells were obtained. The T-cell cultures were activated in vitro with anti-CD3 and anti-CD28, and the proliferation and cytokine production profile were evaluated after 3 days of incubation. The in-vitro HIV-1 replication was measured in culture supernatants in the seventh day following stimulation. The cytokines were also analyzed in the plasma. RESULTS: Our results demonstrated a lower T-cell proliferation and a lower interleukin-1beta, tumor necrosis factor-alpha and interferon-gamma production in polyclonally activated T-cell cultures from G1 patients, when compared with G2. Furthermore, high levels of interleukin-10 were produced both systemically and by activated T-cell cultures from G1 patients. Interestingly, the neutralization of endogenous interleukin-10 by anti-interleukin-10 monoclonal antibody elevated both the inflammatory cytokines' release and the HIV-1 replication in the polyclonally activated T-cell cultures from G1 patients. Additionally, the maternal antiretroviral treatment significantly enhanced the systemic interleukin-10 production. Finally, the higher systemic interleukin-10 levels were inversely correlated with vertical virus transmission risk. CONCLUSION: These results indicate that a high tendency of pregnant women to produce interleukin-10 can help them control the HIV-1 replication, and this can reduce the risk of vertical transmission. Furthermore, our data suggest a role for maternal antiretroviral treatment in enhancing this phenomenon.
OBJECTIVE: This study aimed to evaluate the impact of pregnancy-related immune events on the HIV-1 replication and to analyze their relationship with the risk of vertical transmission. METHODS: The peripheral blood from HIV-1-infected pregnant women who controlled (G1) or not controlled (G2) their plasma viral load was drawn, and the plasma and the T cells were obtained. The T-cell cultures were activated in vitro with anti-CD3 and anti-CD28, and the proliferation and cytokine production profile were evaluated after 3 days of incubation. The in-vitro HIV-1 replication was measured in culture supernatants in the seventh day following stimulation. The cytokines were also analyzed in the plasma. RESULTS: Our results demonstrated a lower T-cell proliferation and a lower interleukin-1beta, tumor necrosis factor-alpha and interferon-gamma production in polyclonally activated T-cell cultures from G1 patients, when compared with G2. Furthermore, high levels of interleukin-10 were produced both systemically and by activated T-cell cultures from G1 patients. Interestingly, the neutralization of endogenous interleukin-10 by anti-interleukin-10 monoclonal antibody elevated both the inflammatory cytokines' release and the HIV-1 replication in the polyclonally activated T-cell cultures from G1 patients. Additionally, the maternal antiretroviral treatment significantly enhanced the systemic interleukin-10 production. Finally, the higher systemic interleukin-10 levels were inversely correlated with vertical virus transmission risk. CONCLUSION: These results indicate that a high tendency of pregnant women to produce interleukin-10 can help them control the HIV-1 replication, and this can reduce the risk of vertical transmission. Furthermore, our data suggest a role for maternal antiretroviral treatment in enhancing this phenomenon.
Authors: Aaron Christensen-Quick; Christophe Vanpouille; Andrea Lisco; Sara Gianella Journal: AIDS Res Hum Retroviruses Date: 2017-11 Impact factor: 2.205
Authors: Dshanta D Naicker; Bingxia Wang; Elena Losina; Jennifer Zupkosky; Susan Bryan; Shabashini Reddy; Manjeetha Jaggernath; Mammekwa Mokgoro; Philip J R Goulder; Daniel E Kaufmann; Thumbi Ndung'u Journal: Clin Infect Dis Date: 2011-11-18 Impact factor: 9.079
Authors: Joana Hygino; Morgana M Vieira; Landi V Guillermo; Renato G Silva-Filho; Carmen Saramago; Agostinho A Lima-Silva; Regis M Andrade; Arnaldao F B Andrade; Rodrigo M Brindeiro; Amilcar Tanuri; Vander Guimarães; Cleonice Alves de Melo Bento Journal: J Clin Immunol Date: 2010-12-07 Impact factor: 8.317
Authors: Olamide D Jarrett; Kirsten E Brady; Sharada P Modur; Jill Plants; Alan L Landay; Mahmood Ghassemi; Elizabeth T Golub; Greg T Spear; Richard M Novak Journal: PLoS One Date: 2015-06-17 Impact factor: 3.240
Authors: Neill J Liptrott; Marco Giardiello; Tom O McDonald; Steve P Rannard; Andrew Owen Journal: J Nanobiotechnology Date: 2018-03-15 Impact factor: 10.435
Authors: Alexander T H Cocker; Nishel M Shah; Inez Raj; Sarah Dermont; Waheed Khan; Sundhiya Mandalia; Nesrina Imami; Mark R Johnson Journal: Front Immunol Date: 2020-02-11 Impact factor: 7.561